Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 29, 2015 16:02 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics to Release First Quarter 2015 Financial Results Wednesday, May 13, 2015

NEWARK, Calif., April 29, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and...
March 02, 2015 16:05 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Releases Fourth Quarter and Full Year 2014 Financial Results and Reiterates 2015 Outlook

NEWARK, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and...
February 26, 2015 17:00 ET | Source: Revance Therapeutics, Inc

Revance Appoints Dr. Philip Vickers to Its Board of Directors

NEWARK, Calif., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
February 17, 2015 16:05 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics, Inc. Announces Participation in Cowen 35th Annual Health Care Conference

NEWARK, Calif., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced that its management is scheduled to participate in the Cowen and Company 35th Annual Health...
February 12, 2015 16:06 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics to Release Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on Monday, March 2, 2015

NEWARK, Calif., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and...
January 12, 2015 07:00 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Defines Clinical Program Milestones and Provides Financial Guidance for 2015

Specifies Milestones for Botulinum Toxin Product Candidates, Topical RT001 and Injectable RT002, for Aesthetic and Therapeutic Indications Updates 2014 Financial Guidance NEWARK, Calif., Jan....
January 08, 2015 16:05 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Announces Publication of Positive Results From RT002 Phase 1/2 Study

RT002 Achieved Median Duration of 7 Months Phase 2 Active Comparator Study Underway NEWARK, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty...
January 05, 2015 07:00 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Announces Initiation of BELMONT Phase 2 Active Comparator Trial of Injectable RT002

NEWARK, Calif., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and...
December 18, 2014 16:05 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Added to NASDAQ Biotechnology Index

NEWARK, Calif., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and...
November 20, 2014 19:20 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics, Inc. Announces Participation in 26th Annual Piper Jaffray Healthcare Conference

NEWARK, Calif., Nov. 20, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...